top of page

Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

  • blonca9
  • Mar 5, 2024
  • 1 min read

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines. He also describes Frontier's platform and a recent $80M series C raise.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page